Substance and claimed effects

Meditation refers to a family of attentional training practices in which the practitioner intentionally regulates attention toward a chosen object — a sensation (breath, body), a concept (loving-kindness), a sound (mantra), or the field of awareness itself — sustained for minutes to hours, typically daily, over weeks to decades. Modern Western clinical research has largely converged on two operationalisations: mindfulness-based interventions (MBIs) — chiefly Mindfulness-Based Stress Reduction (MBSR), an 8-week, ~45-min/day protocol developed by Jon Kabat-Zinn at UMass in 1979 Kabat-Zinn 1982, and its derivative Mindfulness-Based Cognitive Therapy (MBCT), targeted at depressive relapse — and concentrative/mantra practices, principally Transcendental Meditation (TM). Lutz et al. classify practices along two axes: focused attention (single-pointed concentration) versus open monitoring (non-reactive awareness of the field) Lutz et al. 2008. Loving-kindness (metta), body-scan, and analytical contemplations sit in adjacent categories.

Claimed effects with meaningful trial support: reductions in anxiety, depression, perceived stress, chronic-pain interference, insomnia, blood pressure, cortisol reactivity; improvements in sustained attention, working memory, mind-wandering, emotion regulation, interoceptive accuracy, and self-reported wellbeing. Claimed effects with thinner or contested support: telomere length, immune function, inflammatory markers, longevity. This entry covers the consequences holistically — mood, anxiety, attention, pain, sleep, stress physiology, and the burden side (effort, dropout) — across the population of healthy adults using app-based or group-taught practices, with notes on subgroups (clinical depression, chronic pain, trauma history).

Evidence by addressing question

Mechanism

Multiple convergent mechanisms, each with imaging and behavioural support. Amygdala reactivity: Kral et al. found reduced right-amygdala BOLD response to negative emotional images after MBSR, with stronger effects in long-term practitioners; the effect was specific to negative stimuli and persisted at rest Kral et al. 2018. Prefrontal–limbic connectivity: Tang, Hölzel, and Posner's review synthesises evidence that meditation strengthens top-down regulation via increased coupling between dorsolateral and ventromedial prefrontal cortex and the amygdala Tang et al. 2015. Default mode network (DMN) deactivation: Brewer et al. showed experienced meditators have reduced activity in the medial prefrontal cortex and posterior cingulate cortex — DMN hubs associated with self-referential rumination — both during meditation and at rest, with stronger connectivity between DMN and task-positive control regions Brewer et al. 2011. Structural changes: Hölzel et al. found increased grey-matter concentration in the hippocampus, posterior cingulate, temporo-parietal junction, and cerebellum after 8 weeks of MBSR in MRI volumetric analysis Hölzel et al. 2011. HPA axis: Pascoe et al.'s meta-analysis (45 RCTs, ~3,500 participants) reports small-to-moderate reductions in cortisol, blood pressure, heart rate, and triglycerides relative to active controls Pascoe et al. 2017. Pain: Zeidan et al. used fMRI to show that meditation-induced analgesia activates orbitofrontal and rostral anterior cingulate cortex and engages descending pain modulation — distinct from placebo and sham-meditation analgesia, which rely more on opioidergic and expectation pathways Zeidan et al. 2015.

Evidence

Anxiety and depression. Hofmann et al.'s 2010 meta-analysis (39 studies, 1,140 participants) reported pre–post Hedges' g ≈ 0.63 for anxiety symptoms and ≈ 0.59 for mood symptoms in clinical populations Hofmann et al. 2010. The more conservative Goyal et al. AHRQ-funded meta-analysis (47 trials, 3,515 participants) restricted to RCTs with active controls found mindfulness programs produced "moderate evidence" of improvement in anxiety (effect size ≈ 0.38 at 8 weeks), depression (≈ 0.30), and pain — with little to no evidence for substance use, sleep, or weight Goyal et al. 2014. Strauss et al. (12 RCTs in patients with current anxiety/depressive disorder) found post-intervention g ≈ 0.59 for depression and a non-significant effect for anxiety as a primary outcome Strauss et al. 2014. Kuyken et al.'s PREVENT trial (424 adults with ≥3 episodes of recurrent depression) found MBCT non-inferior to maintenance antidepressants for relapse prevention over 24 months (relapse 44% vs 47%) Kuyken et al. 2015. Hoge et al.'s 2023 RCT (276 adults with anxiety disorders) found 8-week MBSR non-inferior to escitalopram on the Clinical Global Impressions–Severity scale at 8 weeks Hoge et al. 2023. Wong et al. (138 adults with generalised anxiety disorder) found MBCT non-inferior to sertraline at 8 weeks Wong et al. 2018.

Chronic pain. Hilton et al.'s meta-analysis (38 RCTs, 3,536 participants) reported small but statistically significant improvements in pain intensity (standardised mean difference ≈ −0.32), depression symptoms, and quality of life, with low-quality evidence for opioid dose reduction Hilton et al. 2017. Cherkin et al.'s 3-arm RCT (342 adults with chronic low back pain ≥3 months) found both MBSR and CBT produced clinically meaningful improvements in functional limitation and back-pain bothersomeness at 26 and 52 weeks, with no significant difference between active arms and both outperforming usual care Cherkin et al. 2016. Mascaro et al.'s 2024 RCT found an app-based mindfulness intervention reduced chronic low-back-pain impact more than usual care over 6 months Mascaro et al. 2024.

Attention and cognition. Jha et al. found 8 weeks of MBSR improved orienting (the alerting and conflict-monitoring subsystems of attention as measured by the Attention Network Test) Jha et al. 2007. Mrazek et al. found a 2-week, ~10-min/day mindfulness course improved working-memory capacity and GRE-Verbal scores, with the effect mediated by reduced mind-wandering Mrazek et al. 2013.

Stress physiology. Davidson et al.'s early RCT (n=48) found 8 weeks of MBSR shifted resting frontal EEG asymmetry leftward (associated with positive affect) and produced larger antibody titres to influenza vaccine Davidson et al. 2003. Pascoe et al. confirmed reductions in cortisol, systolic blood pressure, and heart rate at meta-analytic level Pascoe et al. 2017.

Sleep. Black et al.'s RCT (49 older adults with sleep complaints) found a 6-week mindfulness program improved Pittsburgh Sleep Quality Index scores more than sleep-hygiene education (between-group difference ≈ 2.8 points, comparable to insomnia-targeted interventions) Black et al. 2015.

General wellbeing in non-clinical adults. Galante et al.'s individual-participant-data meta-analysis (136 trials, 11,605 participants in nonclinical settings) reported small-to-moderate reductions in psychological distress (standardised mean difference ≈ −0.32) versus passive controls, attenuated but still present versus active controls Galante et al. 2021. Khoury et al.'s MBSR-in-healthy-adults meta-analysis (29 studies) reported pre–post effect sizes around g ≈ 0.55 for stress, ≈ 0.40 for anxiety, ≈ 0.37 for depression Khoury et al. 2015.

Guideline status. NICE's 2022 depression guideline (NG222) lists group-based mindfulness as a recommended first-line option for less-severe depression and for relapse prevention in recurrent depression — one of a handful of psychological interventions with such status NICE 2022.

Protocol

The canonical clinical dose is the MBSR/MBCT format: 8 weekly group sessions of 2.5 hours, one full-day silent retreat, plus 45 minutes/day of home practice including body-scan, sitting meditation, and gentle yoga. Total commitment ≈ 50–60 hours over 8 weeks. The Wielgosz et al. review notes that trial effect sizes are sensitive to dose: trials reporting <20 min/day of home practice typically underperform Wielgosz et al. 2019. Recent app-based trials (Headspace, Calm, Smiling Mind, Waking Up) compress to 10–20 min/day; Mascaro et al. and Galante et al. confirm meaningful but smaller effects at this dose Mascaro et al. 2024 Galante et al. 2021. The Mrazek 2-week, 10-min/day finding suggests a minimum effective dose around 100–150 minutes of practice for attention outcomes Mrazek et al. 2013. Practice form (focused-attention vs open-monitoring vs loving-kindness) appears to influence which outcomes shift — concentration practices favour attention metrics; open-monitoring favours emotion regulation; loving-kindness uniquely shifts positive affect and social-connectedness measures.

Contraindications

Britton et al.'s prospective study of meditation-related adverse events in MBSR/MBCT participants found that 58% reported at least one transient unpleasant meditation-related experience (anxiety spikes, dissociation, re-experiencing of traumatic content, sleep disruption); 37% reported lasting effects, and 6–14% reported impairments lasting more than a month Britton et al. 2021. Lindahl et al.'s mixed-methods qualitative study of 60 Western Buddhist practitioners catalogued 59 categories of meditation-related challenges, including affective, somatic, perceptual, and self-related disruptions Lindahl et al. 2017. Highest-risk subgroups: prior PTSD or trauma history (body-scan and breath-focused practices can surface trauma material), active psychosis or first-degree relatives with psychotic illness, severe acute depression (rumination amplification risk), and intensive retreat formats (≥1 hour/day or multi-day silent retreats) without trained teacher support. Mild-to-moderate symptoms and routine 10–20 min/day app practice carry materially lower risk than the intensive retreat literature suggests.

Misconceptions

The dominant lay misconception is the "empty-mind" model — that meditation aims to stop thoughts, and that a meditation session with thoughts in it has failed. The instruction across virtually every empirically validated tradition is the opposite: notice when attention has drifted, return to the object, repeat. Mrazek et al.'s mediation analysis explicitly identified reduction in mind-wandering — not absence of thought — as the active mechanism Mrazek et al. 2013. A second misconception is that meditation is intrinsically relaxing; many practices are effortful, and the Britton adverse-event data show that increased anxiety during early sessions is common and not failure Britton et al. 2021. A third is the "I can't meditate" objection grounded in self-reported high baseline mind-wandering — this is exactly the population most likely to benefit per Mrazek's effect-modifier analysis Mrazek et al. 2013.

Audience

Effect-size heterogeneity is substantial. Largest effects: clinical anxiety (Hofmann g ≈ 0.63), recurrent depression in those with multiple prior episodes (Kuyken HR ~equivalent to maintenance ADs), chronic-pain populations with comorbid affective burden. Moderate effects: subclinical anxiety/depression in healthy adults, stress in healthcare workers and caregivers. Smaller or null effects: substance use disorders, eating disorders, smoking cessation as primary endpoints (Goyal). Population responsiveness appears to track baseline rumination, trait neuroticism, and willingness/capacity to do sustained home practice; the strongest single moderator of trial effect size is dose of home practice Wielgosz et al. 2019.

Alternatives

For anxiety/depression: CBT (similar or slightly larger effect sizes per Cuijpers meta-analyses), SSRIs (faster onset, larger pharmacological effect, more side effects), exercise (cardiovascular exercise produces effect sizes ~ 0.4–0.6 for depression and anxiety; see Zou et al. 2018 for meditative-movement comparators). For chronic pain: CBT (comparable per Cherkin), graded exposure, exercise therapy. For attention: stimulant medication (larger acute effect, requires Rx, dependency risk), sleep extension. For stress reactivity: aerobic exercise, social connection, time in nature. Meditation's positioning relative to alternatives is: similar effect size to CBT for mood/anxiety, smaller than first-line pharmacotherapy in acute severe cases, comparable to or better than active control across multiple endpoints, with the lowest cost-burden profile and a uniquely high effort-burden profile per unit effect.

Failure modes

Dropout is the dominant failure mode. MBSR program completion rates in community settings run 60–85%; daily-practice adherence at 12 months without ongoing group structure drops sharply. App-based program completion rates are lower (10–30% sustained use at 6 months in commercial data). Practical failure modes: starting with too-long sessions (40+ minutes for a beginner), self-teaching without instruction calibration (the "am I doing it right?" doubt loop), restricting to formal sitting practice without integration into daily activity (informal practice — noticing during routine activities — is part of the canonical protocol), and treating meditation as a productivity hack rather than an attentional discipline (instrumentalisation tends to backfire on the underlying mechanism). The Wielgosz review notes that effect sizes attenuate when participants stop home practice Wielgosz et al. 2019.

Practicalities

Cost: free if self-directed via open materials (UCLA Mindful, Insight Timer's free tier, public-domain texts); $50–100/year for a major app subscription (Headspace, Calm, Waking Up, Ten Percent Happier); $400–600 for a community-taught 8-week MBSR/MBCT course; insurance coverage for MBCT exists in some UK and US plans where it is part of an integrated care pathway. Equipment: none required; a cushion or chair suffices. Setup time: zero to find materials; the friction is consistency, not access. Where to get it: NHS resources in the UK; Mindfulness-Based Professional Training Institute (UMass) for instructor lookup; major secular apps for self-guided. Time commitment: 10–45 min/day plus weekly group session if course-based.

History

Origins in contemplative traditions across South Asia (Buddhist Vipassana and Samatha, Hindu dhyana and pranayama), East Asia (Zen, Daoist neidan), and Christian/Sufi mystical traditions. Modern secular clinical application begins with Kabat-Zinn's 1979 MBSR program at UMass for chronic-pain patients refractory to medical management Kabat-Zinn 1982, followed by Segal/Williams/Teasdale's MBCT for depressive relapse in the late 1990s, the explosion of imaging studies (Davidson, Lutz, Hölzel) in the 2000s, and the app-driven democratisation in the 2010s. The historical lens is load-bearing: claims that meditation is "ancient and time-tested" are accurate for the practices but not for the modern clinical packaging, which is 40 years old; the trial evidence base is younger still.

Stakes

The stake projection is constructed from the cited evidence base: an adult with baseline subclinical anxiety, daily rumination, and a stress-reactive HPA axis who never meditates continues to experience the documented downstream consequences — chronically elevated cortisol awakening response, larger amygdala reactivity to interpersonal stressors, sustained DMN hyperactivity during off-task time, and elevated risk of progressing from subclinical to clinical anxiety/depression (Hofmann population baselines) Hofmann et al. 2010. The Galante non-clinical meta-analysis shows that the same population, with intervention, sees psychological distress drop with g ≈ 0.32 — meaning the foregone effect is real, modest, and cumulative Galante et al. 2021. For recurrent-depression cohorts, the foregone effect is larger: Kuyken's MBCT arm had a relapse hazard comparable to maintenance antidepressants, suggesting non-adoption costs roughly one prevented relapse per 2–3 years of sustained practice in high-risk subgroups Kuyken et al. 2015.

Payoff

Time course of payoff per the cited trials: at 2 weeks (Mrazek protocol), measurable reductions in mind-wandering and small improvements in working memory Mrazek et al. 2013. At 8 weeks (MBSR/MBCT canonical), moderate effect sizes on anxiety (0.38) and depression (0.30) versus active controls; measurable structural grey-matter changes; reduced amygdala reactivity Goyal et al. 2014 Hölzel et al. 2011 Kral et al. 2018. At 6 months, sleep-quality gains comparable to insomnia-targeted interventions Black et al. 2015; chronic-pain improvement consolidates and persists Cherkin et al. 2016. At 1–2 years, MBCT confers relapse-prevention benefit equivalent to antidepressant maintenance in recurrent depression Kuyken et al. 2015. At 10+ years (long-term meditator cohorts, Tang and Brewer), structural and functional brain differences accumulate beyond what 8-week interventions produce; whether this translates to felt-experience differentials beyond the 8-week range is less rigorously tested.

Out of scope

Adjacent topics not covered: yoga as movement practice (overlap with meditation but distinct trial base), breathwork-only interventions (e.g., Wim Hof, box breathing — different mechanisms), psychedelic-assisted therapy (overlapping outcomes via radically different route), and group-format Buddhist sangha membership as a social intervention.

Credibility range

Optimist case. Meditation is one of the most replicated psychological interventions in modern clinical research: hundreds of RCTs, four+ large meta-analyses across distinct outcomes (anxiety, depression, pain, sleep, attention, stress physiology), structural brain changes documented at 8 weeks, two head-to-head non-inferiority trials versus first-line pharmacotherapy (escitalopram, sertraline) both finding clinical equivalence at 8 weeks, NICE guideline endorsement, and a coherent multi-level mechanism story (amygdala, DMN, prefrontal-limbic connectivity) that ties subjective reports to imaging endpoints. Cost is near zero. The intervention has no pharmacological side-effect profile. The effect-size envelope (Hedges' g ≈ 0.3–0.6 across endpoints) is similar to or exceeds standard psychotherapeutic interventions. Twenty-five centuries of cross-cultural practice provide a base-rate sanity check that the underlying phenomenology is not an artefact of WEIRD trial samples.

Skeptic case. The mindfulness literature is publication-biased and methodologically uneven. Goyal et al.'s key contribution was restricting to active-control RCTs, which roughly halved the effect sizes reported by less-rigorous syntheses Goyal et al. 2014. Many "control" conditions in MBSR trials are passive (waitlist, treatment-as-usual), which inflates effects via expectancy and demand characteristics. The non-inferiority trials versus SSRIs (Hoge, Wong) have modest sample sizes and tested 8-week endpoints, not long-term remission. Adverse events are systematically under-reported (Britton's 58% transient adverse-event rate would be considered unacceptable for a comparator drug) Britton et al. 2021. The chronic-pain effect-size in Hilton (≈ −0.32) is small and not obviously superior to credible-control psychological interventions. The "structural brain changes" finding (Hölzel) has had mixed replication. Long-term meditator cross-sectional studies suffer self-selection bias. The popular conflation of MBSR with traditional contemplative practice elides differences in dose, framework, and intent. The 40% dropout / non-adherence rate in real-world deployment means population-effect size is materially lower than per-protocol effect size.

Author's call. The evidence is strong enough to land firmly on the side that meditation has real, replicated effects on anxiety, depression, chronic pain, attention, and stress reactivity, with effect sizes in the small-to-moderate range — comparable to other first-line psychological interventions and, in head-to-head trials, comparable at 8 weeks to first-line pharmacotherapy for anxiety. The skeptical caveats genuinely move the effect-size estimate downward but do not move the sign or the structural plausibility. The dominant practical concern is not whether meditation works but whether the typical person sustains the dose long enough to capture the effect. The dominant epistemic concern is heterogeneity: effect sizes vary substantially by population, dose, and practice form, and individual response is not well predicted by trial averages. Score evidence at 4 (multiple replicated RCTs, meta-analyses, guideline support) and controversy at 2 (effect-size debate, mostly settled signal direction).

Stakeholder and incentive map

Pro-meditation incentives. Commercial: a multi-billion-dollar app market (Headspace, Calm, Waking Up, Ten Percent Happier, Insight Timer) with strong incentive to claim broad efficacy; corporate-wellness vendors selling MBSR-derived workplace programs; a cottage industry of meditation teachers and retreat centres. Professional: a defined clinical-psychology subfield (Centre for Mindfulness at UMass, Oxford Mindfulness Centre, Centre for Healthy Minds at UW–Madison) with research and training revenue streams. Cultural: Buddhist convert communities, secular Buddhist organisations (Insight Meditation Society, Spirit Rock), and adjacent self-help and biohacking subcultures. Guideline: NICE has folded mindfulness-based programs into recurring-depression management, conferring institutional weight.

Counter-incentives. Competing therapies — CBT practitioners and pharmaceutical interests benefit from positioning meditation as adjunct rather than substitute. Academic skeptics (Britton, Van Dam, Goyal-style methodologists) hold reputation by documenting limitations. Religious traditions of origin sometimes critique secular extraction as decontextualised. The high effort burden creates a natural counter-incentive in commodity attention: every minute meditating is a minute not generating engagement metrics for an app or platform.

Population variability

Effect modifiers documented in the trial literature:

• Baseline severity. Larger effects in clinical anxiety/depression than in subclinical or healthy adults (Hofmann g ≈ 0.63 in clinical vs Galante ≈ 0.32 in non-clinical).
• Recurrence history. MBCT's strongest indication is recurrent depression with three or more prior episodes Kuyken et al. 2015.
• Trauma history. Higher rate of adverse meditation experiences; trauma-sensitive variants (Trauma-Sensitive Mindfulness) developed in response Britton et al. 2021 Lindahl et al. 2017.
• Practice dose. Strongest single moderator across trials; <20 min/day home practice associated with smaller effects Wielgosz et al. 2019.
• Age. Black et al.'s strongest sleep effects in older adults Black et al. 2015; cognitive-attention effects (Mrazek) documented in young adults.
• Cultural background. Most trials in WEIRD samples; transcultural generalisability is plausible from traditional uptake but not formally tested.
• Sex. Most MBSR/MBCT trials skew female (~60–75%); no large sex-specific effect modifier documented.

Knowledge gaps

Open questions where the literature is thin or absent:

• Long-term (5–10 year) trial follow-up. Most RCTs end at 8 weeks to 1 year. Whether the 8-week effect persists, decays, or compounds over a decade is mostly inferred from cross-sectional studies of long-term meditators, which carry selection bias.
• Dose-response curve. Modal trial dose is 45 min/day; modal real-world dose is 10–15 min/day via app. Whether the lower dose produces proportionally smaller effects or sub-threshold effects is incompletely characterised.
• Practice-form specificity. Whether focused-attention vs open-monitoring vs loving-kindness vs mantra produce different outcome profiles is hypothesised (Lutz 2008) but not definitively tested.
• Adverse-event prevention. Which subgroups should not be enrolled in standard MBSR is under-characterised; current guidance is conservative-by-default for trauma and psychosis history.
• Mechanism causality. Imaging findings (amygdala, DMN, grey matter) are correlational; whether they are mediators of clinical effect or epiphenomena is not settled.
• Telomere, inflammation, longevity endpoints. Small studies suggest effects on telomere maintenance and inflammatory markers (IL-6, CRP); replication is sparse and effect sizes uncertain.
• App-based parity. Whether app-based 10–20 min/day matches group-taught MBSR effect size is in active investigation; preliminary signal (Mascaro 2024, Galante 2021) suggests partial parity at lower cost-and-effort.

Coverage vs the brief. The brief listed anxiety, depression, chronic pain, attention, and stress reactivity. All five are covered end-to-end in the evidence and payoff sections with named trial anchors. The brief also asked for "other meditation practices across traditions" — the article gives this lighter treatment than the MBSR/MBCT clinical core. The reason is that the trial evidence base is overwhelmingly built on MBSR/MBCT and (to a lesser extent) TM; making the article a comparative survey of traditions would have diluted the practical guidance without the literature to back the comparisons. The protocol section names the three main families (focused-attention, open-monitoring, loving-kindness) without ranking them, which is the honest call given the literature.

Score holism check. Every non-zero meta dimension has body coverage:

• mood (5) — mechanism, evidence, stakes, payoff
• focus (3) and health_short_term (3) — evidence, payoff
• energy (2), longevity (2), sleep (2) — evidence, payoff, stakes
• cost_burden (1), effort_burden (3) — protocol, practicalities, failure-modes

Rating difficulties.

• beauty_cumulative was provisionally scored 1 (cortisol → skin signature via Pascoe 2017) then dropped to 0. The link is mechanistically real but trial-tested as a meditation endpoint essentially never; including it would have implied a marketing angle the evidence doesn't support.
• evidence at 4, not 5. Hundreds of trials and multiple meta-analyses cleared the bar, but Goyal et al.'s active-control restriction roughly halving the field's effect sizes is the kind of finding that should hold a 5 back.
• mood at 5 rested on the two SSRI non-inferiority trials (Hoge 2023, Wong 2018). Without those, this would have been a 4.
• effort_burden at 3 rather than 2: the clinical dose is 45 min/day, the realistic floor is 10 min/day, and the 12-month adherence problem is the dominant real-world failure mode. Scoring this below 3 would have hidden the central honest catch.

Excluded with reason.

• Transcendental Meditation — referenced briefly but not given a dedicated treatment. The TM literature is genuinely distinct (organisational, mantra-based, with its own RCT base, especially on blood pressure) and crowds out the central mindfulness story when given equal weight. Candidate for a separate entry.
• Trauma-sensitive mindfulness — flagged in contraindications but not detailed. The protocol differences are substantial enough that a separate entry would serve the higher-risk reader better.
• Telomere / inflammation / longevity endpoints — small studies exist but replication is sparse. Mentioned in research's knowledge-gaps section, kept out of the article body.
• Specific app comparisons — naming individual apps in head-to-head order would date the entry quickly and is one app launch away from being wrong.

Separate-entry candidates. Transcendental Meditation; trauma-sensitive mindfulness as a protocol; loving-kindness / metta as a distinct intervention with unique pro-social outcomes; non-sleep deep rest (NSDR / yoga nidra); standalone breathwork protocols.

Future links. Once they exist: yoga, breathwork, nsdr, cardiovascular-exercise, cbt, ssris, chronic-pain, trauma-sensitive-mindfulness, transcendental-meditation.

Hard editorial calls. The contraindications section gives Britton's adverse-event data more prominence than most popular meditation writing does. This is intentional — the mainstream framing of meditation as universally safe is not accurate for trauma and psychosis populations, and the article would be dishonest without it. Calibrated against the trial dose (10–20 min/day app practice) being lower-risk than the intensive-retreat literature.